T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDLN
351
Medline Inc
MDLN
$31.4B
| $308M | 0.03% |
+7,325,104
| New | +$309M |
|
352
Ralph Lauren
RL
$23B
| $307M | 0.03% |
869,070
-85,065
| -9% | -$29M |
|
353
Liberty Media Series C
FWONK
$26B
| $307M | 0.03% |
3,115,395
+212,781
| +7% | +$20.9M |
|
354
Vornado Realty Trust
VNO
$7.43B
| $301M | 0.03% |
9,053,407
+1,598,643
| +21% | +$58.4M |
|
355
Centene
CNC
$32.8B
| $295M | 0.03% |
7,171,568
+2,472,341
| +53% | +$92.5M |
|
356
Kimberly-Clark
KMB
$36.7B
| $294M | 0.03% |
2,917,402
-5,138,358
| -64% | -$562M |
|
357
Advance Auto Parts
AAP
$3.43B
| $294M | 0.03% |
7,474,546
+1,190,094
| +19% | +$59.7M |
|
358
EastGroup Properties
EGP
$11B
| $293M | 0.03% |
1,646,834
-133,626
| -8% | -$23.8M |
|
359
BridgeBio Pharma
BBIO
$15.9B
| $293M | 0.03% |
3,828,746
+2,261,181
| +144% | +$148M |
|
360
Owens Corning
OC
$12.4B
| $290M | 0.03% |
2,594,229
+231,871
| +10% | +$27.2M |
|
361
General Motors
GM
$75.8B
| $287M | 0.03% |
3,526,210
+1,171,612
| +50% | +$82.6M |
|
362
Cadence Design Systems
CDNS
$90B
| $285M | 0.03% |
911,545
-708,193
| -44% | -$231M |
|
363
TotalEnergies
TTE
$193B
| $285M | 0.03% |
4,352,847
+204,233
| +5% | +$12.9M |
|
364
Scholar Rock
SRRK
$6.59B
| $282M | 0.03% |
6,402,437
-480,621
| -7% | -$18M |
|
365
Estee Lauder
EL
$31.7B
| $281M | 0.03% |
2,684,170
+1,171,078
| +77% | +$114M |
|
366
Take-Two Interactive
TTWO
$45.2B
| $280M | 0.03% |
1,093,133
-186,486
| -15% | -$46.5M |
|
367
Vera Therapeutics
VERA
$2.1B
| $277M | 0.03% |
5,461,976
+1,795,537
| +49% | +$63.8M |
|
368
iShares US Real Estate ETF
IYR
$4.58B
| $276M | 0.03% |
+2,942,928
| New | +$280M |
|
369
Blackstone
BX
$110B
| $276M | 0.03% |
1,791,683
+148,964
| +9% | +$22.6M |
|
370
Axsome Therapeutics
AXSM
$11.2B
| $276M | 0.03% |
1,509,870
+472,422
| +46% | +$66M |
|
371
Knife River
KNF
$3.79B
| $275M | 0.03% |
3,915,131
+123,594
| +3% | +$8.68M |
|
372
Johnson Controls International
JCI
$92.4B
| $275M | 0.03% |
2,294,556
+137,119
| +6% | +$15.7M |
|
373
SS&C Technologies
SSNC
$19B
| $274M | 0.03% |
3,133,900
-413,075
| -12% | -$35.2M |
|
374
Millicom
TIGO
$16B
| $274M | 0.03% |
4,936,030
-895,852
| -15% | -$45.1M |
|
375
Amcor
AMCR
$21.5B
| $272M | 0.03% |
6,522,008
+37,973
| +0.6% | +$1.57M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.